Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540631 | 1.00 | KDM4E (0.61) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| SCHEMBL1153491 | 1.00 | KDM4E (0.61) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL4524323 | 0.98 | KDM4E (0.59) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| Water SCHEMBL11513174 | 0.98 | KDM4E (0.59) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| SCHEMBL1828646 | 0.84 | KDM4E (0.58) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| SCHEMBL1234677 | 0.84 | KDM4E (0.58) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| SCHEMBL7258479 | 0.84 | LTA4H (0.58) | LMNASLC6A2MAOASLC6A3SIGMAR1 | |
| SCHEMBL3843513 | 0.83 | SLC6A2 (0.58) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| SCHEMBL14038762 | 0.83 | SLC6A2 (0.58) | KDM4ELMNAMAPK1SLC6A2TAAR1 | |
| SCHEMBL10253191 | 0.83 | SLC6A2 (0.58) | KDM4ELMNAMAPK1SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110724112-A | Bisoxazoline ligand compound and synthetic method thereof | 五邑大学 | 2020-01-24 | — | — | CN | claimed |
| CN-110724112-A | Bisoxazoline ligand compound and synthetic method thereof | 五邑大学 | 2020-01-24 | — | — | CN | disclosed |
| CN-110724112-A | Bisoxazoline ligand compound and synthetic method thereof | 五邑大学 | 2020-01-24 | — | — | CN | disclosed |
| EP-1697308-B1 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7943799-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7842839-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7550481-B2 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550481-B2 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-0942010-B1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymer | SUMITOMO CHEMICAL CO (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6500909-B2 | CONTAINING NICKEL, PALLADIUM, RHODIUM, RUTHENIUM, OR COBALT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-6410741-B1 | INSECTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010027162-A1 | Transition metal compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefinic polymer | HIRAHATA WATARU (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6242377-B1 | POLYMERIZATION IN PRESENCE OF BISOXAZOLINE WITH NICKEL, COBALT, PALLADIUM, RHODIUM, RUTHENIUM, ALUMINUM AND BORON COMPLEXES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6072081-A | Optically active bisoxazoline compounds, production and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-06 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| US-5238955-A | Anticarcinogenic agents | ASTA PHARMA AG (DE) | 1993-08-24 | — | — | US | disclosed |
| US-5194644-A | Antitumor agents; treatment of leukemia | ASTA PHARMA AG (DE) | 1993-03-16 | — | — | US | disclosed |
| EP-0451753-A1 | In the ethylenic moiety substituted phenylalkylethylenediamine-platinum (II or IV) derivatives and phenylalkyl-ethylenediamines | ASTA Medica Aktiengesellschaft (DE) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, GRK7, CYP2A7 | KDM4E 3354/4885LMNA 1389/4885MAPK1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.